- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02247401
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
July 28, 2021 updated by: AbbVie
An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt
This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Non-cirrhotic subjects were directly enrolled into Arm A. Cirrhotic subjects were randomized to either Arm B (12 weeks of treatment) or Arm C (24 weeks of treatment).
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Chronic hepatitis C, genotype 4-infection (hepatitis C virus [HCV] ribonucleic acid [RNA] level greater than 1,000 IU/mL at Screening)
Subjects must meet one of the following:
- Treatment-naive: Subject has never received antiviral treatment for HCV infection OR
- Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegylated-interferon [pegIFN]/RBV);
- Females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control
- In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy or Fibroscan
- In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with Child-Pugh score less than or equal to 6 at Screening and confirmed absence of hepatocellular carcinoma
Exclusion Criteria:
- Females who are pregnant or breastfeeding
- Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus antibody
- HCV genotype performed during screening indicating unable to genotype or co-infection with any other HCV genotype
- abnormal laboratory tests
- self-reports current drinking more than 2 drinks per day
- current enrollment in another investigational study
- previous treatment with a direct acting antiviral agent (DAA) containing regimen
- In substudy 1, evidence of liver cirrhosis
- In substudy 2, evidence of current or past Child-Pugh B or C classification and confirmed presence of hepatocellular carcinoma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A
ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent [DAA]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
|
ABT-450/r/ABT-267 tablets
Ribavirin tablets
|
Active Comparator: Arm B
ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
|
ABT-450/r/ABT-267 tablets
Ribavirin tablets
|
Active Comparator: Arm C
ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
|
ABT-450/r/ABT-267 tablets
Ribavirin tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm
Time Frame: 12 weeks after last dose
|
SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug.
|
12 weeks after last dose
|
Number of Participants With Adverse Events
Time Frame: Screening until 30 days after last dose
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility.
A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
For more details on adverse events please see the Adverse Event section.
|
Screening until 30 days after last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With On-treatment Virologic Failure in Each Treatment Arm
Time Frame: Up to 12 or 24 weeks after first dose
|
On-treatment virologic failure was defined as quantifiable HCV RNA throughout the entire treatment period with at least 6 weeks of treatment, confirmed HCV RNA greater than the LLOQ after previously having unquantifiable HCV RNA, or a confirmed increase from nadir of at least one log10 in HCV RNA during treatment.
|
Up to 12 or 24 weeks after first dose
|
Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm
Time Frame: Up to 12 weeks after first dose
|
Post-treatment relapse was defined as defined as confirmed HCV RNA > LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment.
|
Up to 12 weeks after first dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sarah Kopecky-Bromberg, PhD, AbbVie
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 4, 2014
Primary Completion (Actual)
August 1, 2016
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
September 19, 2014
First Submitted That Met QC Criteria
September 22, 2014
First Posted (Estimate)
September 25, 2014
Study Record Updates
Last Update Posted (Actual)
July 30, 2021
Last Update Submitted That Met QC Criteria
July 28, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M14-250
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCV
-
Ascletis Pharmaceuticals Co., Ltd.Completed
-
Ain Shams UniversityCompleted
-
PfizerCompleted
-
Bristol-Myers SquibbCompletedHCV (Genotype 1)United States, Puerto Rico
-
Gilead SciencesCompletedChronic Genotype 4 HCV | Chronic Genotype 5 HCVFrance
-
Valme University HospitalBoehringer IngelheimUnknown
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Tel-Aviv Sourasky Medical CenterMerck Sharp & Dohme LLCUnknown
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...Completed
Clinical Trials on 2 DAA
-
Universitaire Ziekenhuizen KU LeuvenWithdrawnFemoracetabular ImpingementBelgium
-
National University Hospital, SingaporeCompleted
-
Ottawa Hospital Research InstituteMicroPort Orthopedics Inc.RecruitingArthroplasty, Replacement, HipCanada
-
Arthrex, Inc.RecruitingFull-thickness Rotator Cuff TearUnited States
-
Medical University of WarsawCompletedOsteoarthritis | HipPoland
-
Helse Møre og Romsdal HFSt. Olavs Hospital; Kristiansund HospitalRecruiting
-
Guadarrama HospitalFisiobronquial ClínicasCompleted
-
Hospices Civils de LyonCompleted
-
Ain Shams UniversityUnknownHepatocellular Carcinoma | Hepatitis C, ChronicEgypt
-
Cairo UniversityUnknownInvestigate the Renal Effect of DAAs on Egyption Patients After Completion of TreatmentEgypt